Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Conraux, Laurence ^a   Pech, Catherine ^a   Guerraoui, Halim ^a   Loyaux, Denis ^a   Ferrara, Pascual ^a   Guillemot, Jean Claude ^a   Meininger, Vincent ^b   Pradat, Pierre François ^b   Salachas, François ^b   Bruneteau, Gaëlle ^b   Le Forestier, Nadine ^b   Lacomblez, Lucette ^b  

^a SANOFI   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA2B INTEGRIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; PLASMA PROTEIN; THROMBOCYTE FACTOR 4; THYMOSIN BETA4; UNCLASSIFIED DRUG; ZYXIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84892404809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079733     Document Type: Article

References (36)

1. Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev Neurol 7: 639-749. doi:10.1038/nrneurol.2011.153.
2. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8: 94-109. doi:10.1016/S1474- 4422(08)70293-X. PubMed: 19081518.
3. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR (2010) Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 42: 95-103. doi:10.1002/mus.21625. PubMed: 20544912.
4. Kruger T, Lautenschlager J, Grosskreutz J, Rhode H (2012) Proteome analysis of body fluids for amyotrophic lateral sclerosis (ALS) biomarker discovery. Proteomics Clin Appl (In press).
5. Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M et al. (2010) Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42: 104-111. doi:10.1002/mus.21683. PubMed: 20583124.
6. Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J et al. (2010) Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett 468: 23-27. doi:10.1016/j.neulet.2009.10.053. PubMed: 19853641.
7. Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D et al. (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117: 528-537. doi:10.1111/j.1471-4159.2011.07224.x. PubMed: 21418221.
8. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK et al. (2004) Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76: 1560-1570. doi:10.1021/ac0352171. PubMed: 15018552.
9. Li YH, Wang J, Zheng XL, Zhang YL, Li X et al. (2011) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in parkinson's disease. Eur Neurol 65: 105-111. doi:10.1159/000323427. PubMed: 21273779.
10. Zhang X, Yuan Z, Shen B, Zhu M, Liu C et al. (2011) Discovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads. Clin Exp Med 12: 145-151. PubMed: 21922190.
11. von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P et al. (2012) Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic. PLOS ONE 7: e44401. doi:10.1371/journal.pone.0044401. PubMed: 22970211.
12. Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN et al. (2008) DAnTE: a statistical tool for quantitative analysis of -omics data. Bioinformatics 24: 1556-1558. doi:10.1093/bioinformatics/btn217. PubMed: 18453552.
13. Nesvizhskii Al Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75(17): 4646-4658. doi:10.1021/ac0341261. PubMed: 14632076.
14. Silani V, Messina S, Poletti B, Morelli C, Doretti A et al. (2011) The diagnosis of Amyotrophic lateral sclerosis in 2010. Arch Ital Biol 149: 5-27. PubMed: 21412713.
15. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J et al. (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5: 3262-3277. doi:10.1002/pmic.200401245. PubMed: 16052621.
16. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R et al. P (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4: 1060-1072. doi:10.1021/pr050034b. PubMed: 16083255.
17. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284. PubMed: 16395409.
18. Liang T, Wang N, Li W, Li A, Wang J et al. (2010) Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 10: 90-98. doi:10.1002/pmic. 200900513. PubMed: 19882663.
19. An Y, Bekesova S, Edwards N, Goldman R (2010) Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma. Dis Markers 29: 11-20. doi:10.1155/2010/681876. PubMed: 20826913.
20. Kaneshiro N, Xiang Y, Nagai K, Kurokawa MS, Okamoto K et al. (2009) Comprehensive analysis of short peptides in sera from patients with IgA nephropathy. Rapid Commun Mass Spectrom 23: 3720-3728. doi:10.1002/rcm.4315. PubMed: 19902551.
21. Nanni P (2008) Mass Spectrometry-Based Protein Profiling Strategies For Biomarker Discovery In Liver And Inflammatory Bowel Diseases. Thesis
22. Kawashima Y, Fukutomi T, Tomonaga T, Takahashi H, Nomura F et al. (2010) High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples. J Proteome Res 9: 1694-1705. doi:10.1021/pr9008018. PubMed: 20184378.
23. McNicol A, Israels SJ (2008) Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection. Curr Drug Targets Cardiovasc Haematol Disord: 8: 99-117. doi:10.2174/187152908784533739. PubMed: 18537597.
24. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U et al. (2009) Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 15: 3812-3819. doi:10.1158/1078-0432.CCR-08-2701. PubMed: 19470732.
25. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM (2004) Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ-Res 95(5): 855-857. PubMed: 15459074.
26. Kim JY, Lee JR, Choi S, Kim EM, Jung NK et al. (2013) Quantitative pattern analysis of the N-terminally processed isoforms of platelet factor-4 in serum. Rapid Commun Mass Spectrom 27: 521-530. doi:10.1002/rcm.6480. PubMed: 23322658.
27. Kowalska MA, Rauova L, Poncz M (2010) Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb-Res 125: 292-296. doi:10.1016/j.thromres.2009.11.023. PubMed: 20004006.
28. Vandercappellen J, Van Damme J, Struyf S (2011) The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 22: 1-18. doi:10.1016/j.cytogfr.2010.10.011. PubMed: 21111666.
29. Aidoudi S, Bikfalvi A (2010) nteraction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb-Haemost 104: 941-948. doi:10.1160/TH10-03-0193. PubMed: 20806113.
30. Khansari PS, Sperlagh B (2012) Inflammation in neurological and psychiatric diseases. Inflammopharmacology 20: 103-107. doi:10.1007/s10787-012- 0124-x. PubMed: 22361843.
31. Evans MC, Couch Y, Sibson N, Turner MR (2013) Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol-Cell Neurosci 53: 34-41. doi:10.1016/j.mcn.2012.10.008. PubMed: 23110760.
32. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M (2011) The blood-spinal cord barrier: morphology and clinical implications. Ann-Neurol 2: 194-206. PubMed: 21674586.
33. Arhart RW (2010) A possible haemodynamic mechanism for amyotrophic lateral sclerosis. Med-Hypotheses 75: 341-346. doi:10.1016/j.mehy.2010.03.017. PubMed: 20400230.
34. Behari M, Shrivastava M (2013) Role of platelets in neurodegenerative diseases: a universal pathophysiology. Int J Neurosci 123: 287-299. doi:10.3109/00207454.2012.751534. PubMed: 23301959.
35. Shrivastava M, Das TK, Behari M, Pati U, Vivekanandhan S (2011) Ultrastructural variations in platelets and platelet mitochondria: a novel feature in amyotrophic lateral sclerosis. Ultrastruct Pathol 35: 52-59. doi:10.3109/01913123.2010.541985. PubMed: 21299344.
36. Dupuis L, Spreux-Varoquaux O, Bensimon G, Jullien P, Lacomblez L et al. (2010) Platelet Serotonin Level Predicts Survival in Amyotrophic Lateral Sclerosis. PLOS ONE 5(10): e13346. doi:10.1371/journal.pone.0013346. PubMed: 20967129.